LabCorp Launches Neutralizing Antibody Test for COVID-19 Vaccine Development
The test results could potentially be used in the development of COVID-19 vaccines and the screening of convalescent plasma for prophylactic and therapeutic use.
LabCorp announced on June 25, 2020 that it launched a new test that can be used to assess the capacity of antibodies in patient plasma to inhibit the SARS-CoV-2 virus.
The test results could potentially be used in the development of COVID-19 vaccines and the screening of convalescent plasma for prophylactic and therapeutic use, according to a company press release. It will be available to biopharmaceutical companies, hospitals, blood banks, and other plasma-screening facilities.
“By leveraging our drug development and diagnostic capabilities, we are working tirelessly to find solutions to prevent and treat COVID-19,” said Paul Kirchgraber, MD, CEO, LabCorp’s Drug Development business. “The launch of this neutralizing antibody assay is the latest effort in our company’s commitment to accelerate the evaluation of vaccine candidates so that a successful candidate may reach patients sooner.”
Source: LabCorp
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
